Survey of the Heritability and Sparsity of Gene Expression Traits Across Human Tissues

Heather E. Wheeler<sup>1,2,\*</sup>, Kaanan P. Shah<sup>3</sup>, Jonathon Brenner<sup>2</sup>, Tzintzuni Garcia<sup>4</sup>, Keston Aquino-Michaels<sup>3</sup>, GTEx Consortium, Nancy J. Cox<sup>5</sup>, Dan L. Nicolae<sup>3</sup>, Hae Kyung Im<sup>3,\*</sup>

- 1 Department of Biology, Loyola University Chicago, Chicago, IL, USA
- 2 Department of Computer Science, Loyola University Chicago, Chicago, IL, USA
- 3 Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
- 4 Center for Research Informatics, University of Chicago, Chicago, IL, USA
- 5 Division of Genetic Medicine, Vanderbilt University, Nashville, TN, USA
- \* hwheeler1@luc.edu, haky@uchicago.edu

# Abstract

For most complex traits, gene regulation is known to play a crucial mechanistic role as demonstrated by the consistent enrichment of expression quantitative trait loci (eQTLs) among trait-associated variants. Thus, understanding the genetic architecture of gene expression traits is key to elucidating the underlying mechanisms of complex traits. However, a systematic survey of the heritability and the distribution of effect sizes across all representative tissues in the human body has not been reported.

Here we fill this gap through analyses of the RNA-seq data from a comprehensive set of tissue samples generated by the GTEx Project and the DGN whole blood cohort. We find that local  $h^2$  can be relatively well characterized with 50% of expressed genes

showing significant  $h^2$  in DGN and 8-19% in GTEx. However, the current sample sizes (n < 362 in GTEx) only allow us to compute distal  $h^2$  for a handful of genes (3% in DGN and <1% in GTEx). Thus, we focus on local regulation. Bayesian Sparse Linear Mixed Model (BSLMM) analysis and the sparsity of optimal performing predictors provide compelling evidence that local architecture of gene expression traits is sparse rather than polygenic across DGN and all 40 GTEx tissues examined.

To further delve into the tissue context specificity, we decompose the expression traits into cross-tissue and tissue-specific components. Heritability and sparsity estimates of these derived expression phenotypes show similar characteristics to the original traits. Consistent properties relative to prior GTEx multi-tissue analysis results suggest that these traits reflect the expected biology.

Finally, we apply this knowledge to develop prediction models of gene expression traits for all tissues. The prediction models, heritability, and prediction performance R<sup>2</sup> for original and decomposed expression phenotypes are made publicly available (https://github.com/hakyimlab/PrediXcan).

# **Author Summary**

Gene regulation is known to contribute to the underlying mechanisms of complex traits. The GTEx project has generated RNA-Seq data on hundreds of individuals across more than 40 tissues providing a comprehensive atlas of gene expression traits. Here, we systematically examined the local versus distant heritability as well as the sparsity versus polygenicity of protein coding gene expression traits in tissues across the entire human body. To determine tissue context specificity, we decomposed the expression levels into cross-tissue and tissue-specific components. Regardless of tissue type, we found that local heritability can be well characterized with current sample sizes. Unless strong functional priors and large sample sizes are used, the heritability due to distant variants cannot be estimated. We also find that the distribution of effect sizes is more consistent with a sparse architecture across all tissues. We also show that the cross-tissue and tissue-specific expression phenotypes constructed with our orthogonal tissue decomposition model recapitulate complex Bayesian multi-tissue analysis results. This knowledge was applied to develop prediction models of gene expression traits for

all tissues, which we make publicly available.

Introduction

Regulatory variation plays a key role in the genetics of complex traits [1–3]. Methods that partition the contribution of environment and genetic components are useful tools to understand the biology underlying complex traits. Partitioning heritability into different functional classes has been successful in quantifying the contribution of different mechanisms that drive the etiology of diseases [3–5].

Most human expression quantitative trait loci (eQTL) studies have focused on how local genetic variation affects gene expression in order to reduce the multiple testing burden that would be required for a global analysis [6,7]. Furthermore, when both local and distal eQTLs are reported [8–10], effect sizes and replicability are much higher for local eQTLs. Indeed, while the heritability of gene expression attributable to local genetic variation has been estimated accurately, large standard errors have prevented accurate estimation of the contribution of distal genetic variation to gene expression variation [10,11].

While many common diseases are likely polygenic [12–14], it is unclear whether gene expression levels are also polygenic or instead have simpler genetic architectures. It is also unclear how much these expression architectures vary across genes [6].

The relative prediction performance of sparse and polygenic models can provide useful information about the underlying distribution of effect sizes. For example, if the true model of a trait is polygenic, it is natural to expect that polygenic models will predict better than sparse ones. We assessed the ability of various models, with different underlying assumptions, to predict gene expression in order to both understand the underlying genetic architecture of gene expression and to further optimize predictors for our gene-level association method, PrediXcan [15]. When we calibrated the prediction model that was used in the PrediXcan paper, we showed that sparse models such as LASSO performed better than a polygenic score model. We also showed that a model that uses the top eQTL variant outperformed the polygenic score but did not do as well as LASSO or elastic net [15], suggesting that for many genes, the genetic architecture is sparse, but not regulated by a single SNP.

11

Thus, gene expression traits with sparse architecture should be better predicted with models such as LASSO (Least Absolute Shrinkage and Selection Operator), which prefers solutions with fewer parameters, each of large effect [16]. Conversely, highly polygenic traits should be better predicted with ridge regression or similarly polygenic models that prefer solutions with many parameters, each of small effect [17–19]. To obtain a more thorough understanding of gene expression architecture, we used the hybrid approaches of the elastic net and BSLMM (Bayesian Sparse Linear Mixed Model) [20] to quantify sparse and polygenic effects.

Most previous human eQTL studies were performed in whole blood or lymphoblastoid cell lines due to ease of access or culturabilty [8,21,22]. Although studies with a few other tissues have been published, comprehensive coverage of human tissues was not available until the launching of the Genotype-Tissue Expression (GTEx) Project. GTEx aims to examine the genetics of gene expression more comprehensively and has recently published a pilot analysis of eQTL data from 1641 samples across 43 tissues from 175 individuals [23]. Here we use a much larger set of 8555 samples across 53 tissues corresponding to 544 individuals. One of the findings of this comprehensive analysis was that a large portion of the local regulation of expression traits is shared across multiple tissues. Corroborating this finding, our prediction model based on whole blood showed robust prediction across the 9 core GTEx tissues chosen by initial sample sizes [15].

This shared regulation implies that there is much to be learned from large sample studies of easily accessible tissues. Yet, a portion of gene regulation seems to be tissue dependent [23]. In order to harness this cross-tissue effect for prediction and to better understand the genetic architecture of tissue-specific and cross-tissue gene regulation, we use a mixed effects model called orthogonal tissue decomposition (OTD) to decouple the cross-tissue and tissue-specific mechanisms in the rich GTEx dataset. We modeled the underlying genetic architecture of the cross-tissue and tissue-specific gene expression components and developed predictors for use in PrediXcan [15].

51

Results

#### Local genetic variation can be well characterized for all tissues

We estimated the local and distal heritability of gene expression levels in 40 tissues from the GTEx consortium and whole blood from the Depression Genes and Networks (DGN) cohort. The sample size in GTEx varied from 72 to 361 depending on the tissue, while 922 samples were available in DGN [22]. We used mixed-effects models (see Methods) and calculated variances using restricted maximum likelihood as implemented in GCTA [24].

For the local heritability component, we used variants within 1Mb of the transcription start and end of each protein coding gene, whereas for the distal component, we used variants outside of the chromosome where the gene was located. Different approaches to pick the set of distal variants were explored, but results were robust to different selections. See more details in Methods.

Table 1 summarizes the local heritability estimate results across all tissues. In order to obtain an unbiased estimates of mean  $h^2$ , we allow the values to be negative when fitting the REML (unconstrained), as done previously [10,11]. This approach reduces the standard error of the estimated mean of heritability, especially important for the distal component. Even though each individual gene's distal heritability is noisy, averaging across all genes reduces the error substantially. For the DGN dataset, we were able to estimate the mean distal  $h^2$ , which was 0.034 (SE = 0.0024). However for the GTEx samples, the sample size was too small and the REML algorithm became unstable when allowing for negative values. This numeric instability would cause only a small number of genes with large positive (and noisy) heritability values to converge biasing the mean value. For this reason we do not show mean distal heritability estimates for GTEx tissues.

The left column of Fig. 1 shows the estimated local and distal  $h^2$  from DGN. Even though many genes show relatively large point estimates of distal  $h^2$ , only the ones colored in blue are significantly different from zero (P < 0.05). The local component of  $h^2$  is relatively well estimated in DGN with 50% of genes (6399 out of 12719) showing P < 0.05. In contrast, the distal heritability is significant for only 7.3% (931 out of 12719) of the genes (P < 0.05). This is not much larger than the expected number at

Table 1. Estimates of unconstrained local  $\mathbf{h}^2$  across genes within tissues.

table 1. Estimates of unconstrained for		across genes v			
tissue	n	mean h <sup>2</sup> (SE)	% P < 0.05	num $P < 0.05$	num expressed
DGN Whole Blood	922	0.143 (0.0015)	50.3	6399	12719
Cross-tissue	450	$0.062 \ (0.0008)$	35.4	6003	16951
Adipose - Subcutaneous	298	$0.038 \ (0.0008)$	16.9	2402	14205
Adrenal Gland	126	$0.043 \ (0.0011)$	11.4	1610	14150
Artery - Aorta	198	$0.042\ (0.0010)$	16.6	2294	13844
Artery - Coronary	119	$0.037 \ (0.0010)$	10.5	1477	14127
Artery - Tibial	285	$0.042 \ (0.0009)$	17.3	2333	13504
Brain - Anterior cingulate cortex (BA24)	72	$0.028 \ (0.0015)$	10.6	1532	14515
Brain - Caudate (basal ganglia)	100	$0.037 \ (0.0012)$	10.5	1540	14632
Brain - Cerebellar Hemisphere	89	0.049 (0.0014)	13.3	1901	14295
Brain - Cerebellum	103	$0.050 \ (0.0013)$	13.5	1955	14491
Brain - Cortex	96	$0.045\ (0.0012)$	10.7	1575	14689
Brain - Frontal Cortex (BA9)	92	$0.038\ (0.0013)$	10.9	1581	14554
Brain - Hippocampus	81	$0.037\ (0.0013)$	9.8	1422	14513
Brain - Hypothalamus	81	$0.017\ (0.0013)$	9.9	1460	14759
Brain - Nucleus accumbens (basal ganglia)	93	0.029(0.0012)	10.2	1486	14601
Brain - Putamen (basal ganglia)	82	$0.032\ (0.0013)$	10.1	1456	14404
Breast - Mammary Tissue	183	$0.029\ (0.0008)$	11.7	1714	14700
Cells - EBV-transformed lymphocytes	115	$0.058\ (0.0013)$	11.6	1448	12454
Cells - Transformed fibroblasts	272	$0.051\ (0.0010)$	19.0	2420	12756
Colon - Sigmoid	124	$0.033\ (0.0011)$	12.3	1760	14321
Colon - Transverse	170	$0.036\ (0.0009)$	12.5	1832	14676
Esophagus - Gastroesophageal Junction	127	$0.032\ (0.0010)$	11.6	1638	14125
Esophagus - Mucosa	242	$0.042\ (0.0009)$	17.4	2476	14239
Esophagus - Muscularis	219	$0.039\ (0.0009)$	16.8	2355	14047
Heart - Atrial Appendage	159	$0.042\ (0.0010)$	12.9	1787	13892
Heart - Left Ventricle	190	$0.034\ (0.0009)$	14.7	1960	13321
Liver	98	$0.033\ (0.0012)$	10.0	1350	13553
Lung	279	0.032(0.0007)	15.7	2315	14775
Muscle - Skeletal	361	$0.033\ (0.0007)$	17.0	2180	12833
Nerve - Tibial	256	$0.052\ (0.0009)$	18.8	2724	14510
Ovary	85	$0.037\ (0.0013)$	8.5	1194	14094
Pancreas	150	$0.047\ (0.0011)$	14.0	1954	13941
Pituitary	87	0.038 (0.0013)	10.7	1621	15183
Skin - Not Sun Exposed (Suprapubic)	196	0.041 (0.0009)	13.4	1966	14642
Skin - Sun Exposed (Lower leg)	303	0.039 (0.0008)	17.7	2589	14625
Small Intestine - Terminal Ileum	77	0.036 (0.0014)	9.0	1341	14860
Spleen	89	0.059 (0.0014)	10.4	1508	14449
Stomach	171	0.032 (0.0009)	12.0	1747	14531
Testis	157	0.052 (0.0003) 0.054 (0.0010)	16.5	2792	16936
Thyroid	279	0.044 (0.0009)	18.2	2670	14642
Whole Blood	339	0.033 (0.0008)	16.1	1956	12160
Front for DCN Whole Plead all tiggues are		\ /			areasien levels for

Except for DGN Whole Blood, all tissues are from the GTEx Project. Cross-tissue uses derived expression levels from our orthogonal tissue decomposition (OTD) of GTEx data. Mean heritability ( $h^2$ ) and the standard error of the mean (SE) are calculated across genes for each tissue. The percentage (%) and number (num) of genes with significant  $h^2$  estimates (P < 0.05) and the number of genes expressed in each tissue are also reported.

this significance level (5%) and the genes with P < 0.05 and negative  $h^2$  in Fig. 1 are obvious false positives, within the type 1 error rate.




Figure 1. DGN whole blood expression local and distal heritability ( $h^2$ ). This figure shows the local and distal heritability of gene expression levels in whole blood from the DGN RNA-seq dataset. In order to obtain an unbiased estimates of mean  $h^2$ , we allow the values to be negative when fitting the REML (unconstrained). Notice that only a few genes have distal heritability that is significantly different from 0 (P < 0.05). Local was defined as 1Mb from each gene. For the left side panel, distal heritability was computed using all SNPs outside of the gene's chromosome. On the the right side, distal heritability was computing using SNPs that were cis-eQTLs in the Framingham study. (**Top**) Distal  $h^2$  compared to local  $h^2$  per gene in each model. (**Middle**) Local and (**Bottom**) distal gene expression  $h^2$  estimates ordered by increasing  $h^2$ . As a measure of uncertainty, we have added two times the standard errors of each  $h^2$  estimate in gray segments. Genes with significant  $h^2$  (P < 0.05) are shown in blue. To be conservative, we set  $h^2 = 0$  when GCTA did not converge. Genes in blue with negative  $h^2$  are false positives, within the type 1 error (5%).

It has been shown that local-eQTLs are more likely to be distal-eQTLs of target genes [25]. Thus, we tested whether restricting the distal genetic similarity computation to QTLs (as determined in the Framingham mRNA dataset of over 5000 individuals [26] independent of the DGN and GTEx cohorts) for other genes could improve distal heritability precision by prioritizing functional variants. We exclude eQTLs on the same chromosome as the tested gene to avoid contaminating distal h<sup>2</sup> with cis associations.

While using functional priors (known eQTLs) to define distal  $h^2$  decreased the mean standard error of the heritability estimates across genes from 0.24 to 0.14, the number of significant genes did not change dramatically (Fig. 1). Also, using the subset of known eQTLs (from an independent source) in other chromosomes for computing distal heritability reduced the mean value from 0.027 to 0.015. Therefore, while we gain some power to detect significant distal heritability by using cis eQTL priors as indicated by the standard error reduction, a good portion of the distal regulation is lost when using only the smaller subset of known cis-eQTL variants. We used functional priors to estimate distal  $h^2$  in the GTEx cohort, but less than 1% of genes had a P < 0.05 (S1 Fig).

Given the limited sample size we will focus on local regulation for the remainder of the paper.

# Sparse local architecture implied by sparsity of best prediction models

Next, we sought to determine whether the local genetic contribution to gene expression is polygenic or sparse. In other words, whether many variants with small effects or a small number of large effects were contributing to expression trait variability. For this, we first looked at the prediction performance of a range of models with different degrees of polygenicity, such as the elastic net model with mixing parameter values ranging from 0 (fully polygenic, ridge regression) to 1 (sparse, LASSO).

More specifically, we performed 10-fold cross-validation using the elastic net [27] to test the predictive performance of local SNPs for gene expression across a range of mixing parameters ( $\alpha$ ). The mixing parameter that yields the largest cross-validation  $\mathbb{R}^2$  informs the degree of sparsity of each gene expression trait. That is, at one extreme,

if the optimal  $\alpha=0$  (equivalent to ridge regression), the gene expression trait is highly polygenic, whereas if the optimal  $\alpha=1$  (equivalent to LASSO), the trait is highly sparse. We found that for most gene expression traits, the cross-validated  $R^2$  was smaller for  $\alpha=0$  and  $\alpha=0.05$ , but nearly identically for  $\alpha=0.5$  through  $\alpha=1$  in the DGN cohort (Fig. 2). An  $\alpha=0.05$  was also clearly suboptimal for gene expression prediction in the GTEx tissues, while models with  $\alpha=0.5$  or 1 had similar predictive power (S2 Fig). This suggests that for most genes, the effect of local genetic variation on gene expression is sparse rather than polygenic.




Figure 2. DGN cross-validated predictive performance across the elastic net. This figure shows the cross validated  $R^2$  between observed and predicted expression levels using elastic net prediction models in DGN. (A) This panel shows the 10-fold cross validated  $R^2$  for 51 genes with  $R^2 > 0.3$  from chromosome 22 as a function of the elastic net mixing parameters ( $\alpha$ ). Smaller mixing parameters correspond to more polygenic models while larger ones correspond to more sparse models. Each line represents a gene. The performance is in general flat for most values of the mixing parameter except very close to zero where it shows a pronounced dip. Thus polygenic models perform more poorly than sparse models. (B) This panel shows the difference between the cross validated  $R^2$  of the LASSO model and the elastic net model mixing parameters 0.05 and 0.5 for autosomal protein coding genes. Elastic net with  $\alpha = 0.5$  values hover around zero, meaning that it has similar predictive performance to LASSO. The  $R^2$  difference of the more polygenic model (elastic net with  $\alpha = 0.05$ ) is mostly above the 0 line, indicating that this model performs worse than the LASSO model.

# Direct estimation of sparsity using BSLMM also points to sparse local architecture

To further confirm the local sparsity of gene expression traits, we turned to the BSLMM [20] approach, which models the genetic contribution as the sum of a sparse and a polygenic component. The parameter PGE in this model represents the

129

131

132

133

123

125

127

proportion of genetic variance explained by sparse effects. Another parameter, the total variance explained (PVE) by additive genetic variants, is a more flexible Bayesian equivalent of the chip heritability we have estimated using a linear mixed model (LMM) as implemented in GCTA.

As anticipated, we find that for highly heritable genes, the sparse component is large. For example, all genes with PVE > 0.50 had PGE > 0.82 and their median PGE was 0.989 (Fig. 3A). The median PGE for genes with PVE > 0.1 was 0.949. Fittingly, for most (96.3%) of the genes with PVE estimates > 0.10, the median number of SNPs included in the model was no more than 10.




Figure 3. Sparsity estimates using Bayesian Sparse Linear Mixed Models. (A) This panel shows a measure of sparsity of the gene expression traits represented by the PGE parameter from the BSLMM approach. PGE is the proportion of the sparse component of the total variance explained by genetic variants, PVE (the BSLMM equivalent of  $h^2$ ). The median of the posterior samples of BSLMM output is used as estimates of these parameters. Genes with a lower credible set (LCS) > 0.01 are shown in blue and the rest in red. The 95% credible set of each estimate is shown in gray. For highly heritable genes the sparse component is close to 1, thus for high heritability genes the local architecture is sparse. For lower heritability genes, there is not enough evidence to determine sparsity or polygenicity. (B) This panel shows the heritability estimate from BSLMM (PVE) vs the estimates from GCTA, which are found to be similar (R=0.96).

## BSLMM outperforms LMM in estimating h<sup>2</sup> for small samples

Also as expected, we find that when the sample size is large enough, such as in DGN, there is a strong correlation between BSLMM-estimated PVE and GCTA-estimated h<sup>2</sup> (Fig. 3B, R=0.96). In contrast, when we applied BSLMM to the GTEx data, we found that many genes had measurably larger BSLMM-estimated PVE than GCTA-estimated

143

136

137

138

140

141

 $h^2$  (Fig. 4). This is further confirmation of the local sparse architecture of gene expression traits: the underlying assumption in the GCTA (LMM) approach to estimate heritability is that the genetic effect sizes are normally distributed, i.e. most variants have small effect sizes. LMM is quite robust to departure from this assumption, but only when the sample size is rather large. For the relatively small sample sizes in GTEx  $(n \le 361)$ , we found that a model that directly addresses the sparse component such as BSLMM outperforms GCTA for estimating  $h^2$ .




Figure 4. BSLMM vs LMM estimates of heritability in GTEx. This figure shows the comparison between estimates of heritability using BSLMM vs LMM for GTEx data. For most genes BSLMM estimates are larger than LMM estimates reflecting the fact that BSLMM yields better estimates of heritability because of its ability to account for the sparse component. R = Pearson correlation.

150

151

152

# Orthogonal decomposition of cross-tissue and tissue-specific expression traits

Since a substantial portion of local regulation was shown to be common across multiple tissues [23], we sought to decompose the expression levels into a component that is common across all tissues and tissue-specific components. For this we use a linear mixed effects model with a person-level random effect. See details in Methods. We use the posterior mean of this random effect as an estimate of the cross tissue component. We consider the residual component of this model as the tissue specific component. Below we describe the properties of these derived phenotypes.

We call this approach orthogonal tissue decomposition (OTD) because the cross-tissue and tissue-specific components are assumed to be independent in the model. The decomposition is applied at the expression trait level so that the downstream genetic regulation analysis is performed separately for each derived trait, cross-tissue and tissue-specific expression, which greatly reduces computational burden. For all the derived phenotypes, one cross-tissue and 40 tissue-specific ones, we computed the local heritability and generated prediction models.

# Cross-tissue expression phenotype is less noisy and shows higher predictive performance

Our estimates of  $h^2$  for cross tissue expression traits are larger than the corresponding estimates for each whole tissue expression traits (S3 Fig). This is due to the fact that our OTD approach increases the ratio of genetically regulated component to noise by averaging across multiple tissues. In addition to the increased  $h^2$  we observe reduction in standard errors of the estimated  $h^2$ . This is partly due to the increased  $h^2$  – higher  $h^2$  are better estimated – but also due to the larger effective sample size for cross tissue phenotypes. There were 450 samples for which cross tissue traits were available whereas the maximum sample size for whole tissue phenotypes was 362. As consequence of this increased  $h^2$  and decreased standard errors, the percentage of cross  $h^2$  estimates with P < 0.05 was 35.4% whereas for whole tissue expression traits they ranged from 8.5-19.0% (Table 1). Similarly, cross-tissue BSLMM PVE estimates had lower error than whole tissue PVE (S4 Fig, S5 Fig).

As for the tissue-specific components, the cross-tissue heritability estimates were also larger and the standard errors were smaller reflecting the fact that a substantial portion of regulation is common across tissues (S6 Fig). The percentage of GCTA  $h^2$  estimates with P < 0.05 was much larger for cross-tissue expression (35.4%) than the tissue-specific expressions (7.6-17.7%, S1 Table). Similarly, the percentage of BSLMM PVE estimates with a lower credible set greater than 0.01 was 49% for cross-tissue expression, but ranged from 24-27% for tissue-specific expression (S5 Fig).

Cross-tissue predictive performance exceeded that of both tissue-specific and whole tissue expression as indicated by higher cross-validated R<sup>2</sup> (S2 Fig, S7 Fig). Like whole tissue expression, cross-tissue and tissue-specific expression showed better predictive performance when using more sparse models. In other words elastic-net models with  $\alpha > 0.5$  predicted better than the ones with  $\alpha = 0.05$  (S7 Fig).

# Cross Tissue expression phenotype recapitulates published multi-tissue eQTL results

To verify that the cross tissue phenotype has the properties we expect, we compared our OTD results to those from a joint multi-tissue eQTL analysis [28], which was previously performed on a subset of the GTEx data [23] covering 9 tissues. In particular, we used the posterior probability of a gene being actively regulated (PPA) in a tissue. These analysis results are available on the GTEx portal.

First, we reasoned that genes with high cross tissue h<sup>2</sup> would be actively regulated in most tissues so that the PPA of a gene would be roughly uniform across tissues. By contrast, a gene with tissue specific regulation would have concentrated posterior probability in one or a few tissues. Thus we decided to define a measure of uniformity of the posterior probability vector across the 9 tissues using the concept of entropy. More specifically, for each gene we normalized the vector of posterior probabilities so that the sum equaled 1. Then we applied the usual entropy definition (negative of the sum of the log of the posterior probabilities weighted by the same probabilities, see Methods). In other words, we defined a uniformity statistic that combines the nine posterior probabilities into one value such that higher values mean the gene regulation is more uniform across all nine tissues, rather than in just a small subset of the nine.

Thus we expected that genes with high cross tissue heritability, i.e. large cross tissue regulation would show high probability of being active in multiple tissues, thus high uniformity measure. Reassuringly, this is exactly what we find. Figure 5 shows that genes with high cross tissue heritability concentrate on the higher end of the uniformity measure.




Figure 5. Measure of uniformity of the posterior probability of active regulation vs. cross-tissue heritability. This figure shows the distribution of heritability of the cross-tissue component vs. a measure of uniformity of genetic regulation across tissues. The measure of uniformity was computed using the posterior probability of a gene being actively regulated in a tissue, PPA, from the Flutre et al. [28] multi-tissue eQTL analysis. Genes with PPA concentrated in one tissue were assigned small values of the uniformity measure whereas genes with PPA uniformly distributed across tissues were assigned high value of uniformity measure. See Methods for the entropy-based definition of uniformity.

For the original whole tissue, we expected the whole tissue expression heritability to correlate with the posterior probability of a gene being actively regulated in a tissue. This is confirmed in Figure 6A where PPA in each tissue is correlated with the BSLMM PVE of the expression in that tissue. In the off diagonal elements we observe high correlation between tissues, which was expected given that large portion of the regulation has been shown to be common across tissues. Whole blood has the lowest correlation consistent with whole blood clustering aways from other tissues [23]. In contrast, panel B of Figure 6 shows that the tissue specific expression PVE correlates well with matching tissue PPA but the off diagonal correlations are substantially reduced consistent with these phenotypes representing tissue specific components. Again whole blood shows a negative correlation which could be indicative of some over correction of the cross tissue component. Overall these results indicate that the cross

tissue and tissue-specific phenotypes have properties that are consistent with the intended decomposition.




Figure 6. Comparison of heritability of whole tissue or tissue specific components vs. PPA. Panel (A) of this figure shows the Pearson correlation (R) between the BSLMM PVE of the original (we are calling whole here) tissue expression levels vs. the probability of the tissue being actively regulated in a given tissue (PPA). Matching tissues show, in general, the largest correlation values but most of the off diagonal correlations are also relatively high consistent with the shared regulation across tissues. Panel (B) shows the Pearson correlation between the PVE of the tissue-specific component of expression via orthogonal tissue decomposition (OTD) vs. PPA. Correlations are in general lower but matching tissues show the largest correlation. Off diagonal correlations are reduced substantially consistent with properties that are specific to each tissue. Area of each circle is proportional to the absolute value of R.

Discussion

Motivated by the key role that regulatory variation plays in the genetic control of complex traits [1–3], we performed a survey of the heritability and patterns of effect sizes of gene expression traits across a comprehensive set of human tissues. We quantified the local and distal heritability of gene expression in DGN and 40 different tissues from the GTEx consortium. For the DGN dataset, we estimate the relative proportion of mean local and distal genetic contribution to gene expression traits. For GTEx samples it was not possible to estimate the mean distal heritability because of the limited sample size. As the number of GTEx samples grows to near 1000 individuals, we expect to be able to estimate these values.

In DGN (whole blood), the mean local  $h^2$  was 14.3% and the mean distal  $h^2$  was 3.4% such that the local variation contribution is estimated as 14.3/(3.4+14.3)=81%. This is much higher than the 37% reported by Price et al. [11] based on blood

expression data from a cohort of Icelandic individuals. This potentially underestimation of the distal component could be due to over-correction of confounders used in the preprocessing of the expression trait data we used. Indeed, PEER [29], SVA [30], and other types of hidden confounder corrections have been shown to increase local eQTL replicability, but their consequences on distal regulation is not well understood. As larger sample sizes become available, we will test this hypothesis in GTEx data by computing the distal h<sup>2</sup> without PEER factor correction.

We showed that restricting distal variants to known functional variants such as eQTL data from independent studies improves the precision of distal heritability estimates, but also reduces mean distal heritability estimates by half.

Using results implied by the improved predictive performance of sparse models and by directly estimating sparsity using BSLMM (Bayesian Sparse Linear Mixed Model), we show evidence that for highly heritable genes, local regulation is sparse across all the tissues analyzed here. For genes with moderate and low heritability the evidence is not as strong, but results are consistent with a sparse local architecture. Better methods to correct for hidden confounders that do not dilute distal signals and larger sample sizes will be needed to determine the properties of distal regulation.

Given that a substantial portion of local regulation is shared across tissues, we propose here to decompose the expression traits into cross-tissue and tissue-specific components. This approach, called orthogonal tissue decomposition, aims to decouple the shared regulation from the tissue-specific regulation. We examined the genetic architecture of these derived traits and find that they follow similar patterns to the original whole tissue expression traits. The cross-tissue component benefits from an effectively larger sample size than any individual tissue trait, which is reflected in more accurate heritability estimates and consistently better prediction performance. Encouragingly, we find that genes with high cross tissue heritability tend to be regulated

Prediction models of these decoupled expression traits will be useful to interpret the association results from PrediXcan [15]. We expect results from the cross-tissue models to relate to mechanisms that are shared across multiple tissues whereas results from the tissue-specific models will inform us about the context specific mechanisms.

more uniformly across tissues. As for the tissue-specific expression traits, we found that

they recapitulate correlation with the vector of probability of tissue-specific regulation.

249

251

253

255

257

262

264

267

269

271

272

273

277

In this paper, we quantitate the genetic architecture of gene expression and develop predictors across tissues. We show that local heritability can be accurately estimated across tissues, but distal heritability cannot be reliably estimated at current sample sizes. Using two different approaches, the elastic net and BSLMM, we show that for local gene regulation, the genetic architecture is mostly sparse rather than polygenic. Using new expression phenotypes generated in our OTD model, we show that cross-tissue predictive performance exceeded that of both tissue-specific and whole tissue expression as indicated by higher elastic net cross-validated R<sup>2</sup>. Predictors, heritability estimates and cross-validation statistics generated in this study of gene expression architecture have been added to our PredictDB database (https://github.com/hakyimlab/PrediXcan) for use in future studies of complex trait genetics.

# Materials and Methods

### Genomic and Transcriptomic Data

DGN Dataset. We obtained whole blood RNA-seq and genome-wide genotype data for 922 individuals from the Depression Genes and Networks (DGN) cohort [22], all of European ancestry. For our analyses, we used the HCP (hidden covariates with prior) normalized gene-level expression data used for the trans-eQTL analysis in Battle et al. [22] and downloaded from the NIMH repository. The 922 individuals were unrelated (all pairwise  $\hat{\pi} < 0.05$ ) and thus all included in downstream analyses. Imputation of approximately 650K input SNPs (minor allele frequency [MAF] > 0.05, Hardy-Weinberg Equilibrium [P > 0.05], non-ambiguous strand [no A/T or C/G SNPs]) was performed on the Michigan Imputation Server (https://imputationserver.sph.umich.edu/start.html) [31,32] with the following parameters: 1000G Phase 1 v3 ShapeIt2 (no singletons) reference panel, SHAPEIT phasing, and EUR population. Approximately 1.9M non-ambiguous strand SNPs with MAF > 0.05, imputation  $\mathbb{R}^2 > 0.8$  and, to reduce computational burden, inclusion in HapMap Phase II were retained for subsequent analyses.

281

283

291

299

301

303

GTEx Dataset. We obtained RNA-seq gene expression levels from 8555 tissue samples (53 unique tissue types) from 544 unique subjects in the GTEx Project [23] data release on 2014-06-13. Of the individuals with gene expression data, genome-wide genotypes (imputed with 1000 Genomes) were available for 450 individuals. While all 8555 tissue samples were used in the OTD model (described below) to generate cross-tissue and tissue-specific components of gene expression, we used the 40 tissues with the largest sample sizes when quantifying tissue-specific effects (see Table 1). Approximately 2.6M non-ambiguous strand SNPs included in HapMap Phase II were retained for subsequent analyses.

Framingham Expression Dataset. We obtained exon array expression and genotype array data from 5257 individuals from the Framingham Heart Study [26]. The final sample size after QC was 4286. We used the Affymetrix power tools (APT) suite to perform the preprocessing and normalization steps. First the robust multi-array analysis (RMA) protocol was applied which consists of three steps: background correction, quantile normalization, and summarization [33]. The background correction step uses antigenomic probes that do not match known genome sequences to adjust the baseline for detection, and is applied separately to each array. Next, the normalization step utilizes a 'sketch' quantile normalization technique instead of a memory-intensive full quantile normalization. The benefit is a much lower memory requirement with little accuracy trade-off for large sample sets such as this one. Finally, the adjusted probe values were summarized (by the median polish method) into log-transformed expression values such that one value is derived per exon or gene. Additionally an analysis of the detection of probes above the background noise (DABG) was carried out. It provides further diagnostic information which can be used to filter out poorly performing probes and weakly expressed genes. The summarized expression values were then annotated more fully using the annotation databases contained in the huex10stprobeset.db (exon-level annotations) and huex10sttranscriptcluster.db (gene-level annotations) R packages available from Bioconductor [34,35]. In both cases gene annotations were provided for each feature.

Plink [36] was used for data wrangling and cleaning steps. The data wrangling steps included updating probe IDs, unifying data to the positive strand, and updating

309

311

312

313

314

315

316

318

319

320

321

322

323

327

329

330

331

332

334

locations to GRCh37. The data cleaning steps included a step to filter for variant and subject missingness and minor alleles, one to filter variants with Hardy-Weinberg exact test, and a step to remove unusual heterozygosity. Additionally, we used the HRC-check-bin tool in order to carry out data wrangling steps required to make our data compatible with the Haplotype Reference Consortium (HRC) panel (http://www.well.ox.ac.uk/~wrayner/tools/). Having been prepared thusly, the data were split by chromosome and pre-phased with SHAPEIT [37] using the 1000 Genomes phase 3 panel and converted to vcf format. These files were then submitted to the Michigan Imputation Server (https://imputationserver.sph.umich.edu/start.html) [31,32] for imputation with the HRC version 1 panel [38]. We applied Matrix eQTL [39] to the normalized expression and imputed genotype data to generate prior eQTLs for our heritability analysis.

#### Partitioning local and distal heritability of gene expression

Motivated by the observed differences in regulatory effect sizes of variants located in the vicinity of the genes and distal to the gene, we partitioned the proportion of gene expression variance explained by SNPs in the DGN cohort into two components: local (SNPs within 1Mb of the gene) and distal (eQTLs on non-gene chromosomes) as defined by the GENCODE [40] version 12 gene annotation. We calculated the proportion of the variance (narrow-sense heritability) explained by each component using the following mixed-effects model:

$$Y_g = \sum_{k \in local} w_{k,g}^{local} X_k + \sum_{k \in distal} w_{k,g}^{distal} X_k + \epsilon$$

where  $Y_g$  represents the expression of gene g,  $X_k$  is the allelic dosage for SNP k, local refers to the set of SNPs located within 1Mb of the gene's transcription start and end, distal refers to SNPs in other chromosomes, and  $\epsilon$  is the error term representing environmental and other unknown factors. We assume that the local and distal components are independent of each other as well as independent of the error term. We assume random effects for  $w_{k,g}^{\text{local}} \sim N(0, \sigma_{w,\text{local}}^2)$ ,  $w_{k,g}^{\text{distal}} \sim N(0, \sigma_{w,\text{distal}}^2)$ , and  $\epsilon \sim N(0, \sigma_{\epsilon}^2 I_n)$ , where  $I_n$  is the identity matrix. We calculated the total variability

explained by local and distal components using restricted maximum likelihood (REML) as implemented in the GCTA software [24].

For the purpose of estimating the mean heritability (see Table 1, Figure 1 and S1 Table), we allowed the heritability estimates to take negative values (unconstrained model). Despite the lack of obvious biological interpretation of a negative heritability, it is an accepted procedure used in order to avoid bias in the estimated mean [10,11]. Heritabilities are plotted as point estimates with bars that extend 2 times the estimated standard error up and down. Genes were considered to have heritability significantly different from 0 if the p value from GCTA was less than 0.05.

For comparing to BSLMM PVE, we restricted the GCTA heritability estimates to be within the [0,1] interval (constrained model, see Figures 3, 4 and 5).

### Determining polygenicity versus sparsity using the elastic net

We used the glmnet package to fit an elastic net model where the tuning parameter is chosen via 10 fold cross validation to maximize prediction performance measured by Pearson's  $\mathbb{R}^2$  [41, 42].

The elastic net penalty is controlled by mixing parameter  $\alpha$ , which spans LASSO ( $\alpha=1$ , the default) [16] at one extreme and ridge regression ( $\alpha=0$ ) [17] at the other. The ridge penalty shrinks the coefficients of correlated SNPs towards each other, while the LASSO tends to pick one of the correlated SNPs and discard the others. Thus, an optimal prediction  $R^2$  for  $\alpha=0$  means the gene expression trait is highly polygenic, while an optimal prediction  $R^2$  for  $\alpha=1$  means the trait is highly sparse.

In the DGN cohort, we tested 21 values of the mixing parameter  $(\alpha=0,0.05,0.1,...,0.90,0.95,1)$  for optimal prediction of gene expression of the 341 genes on chromosome 22. For the rest of the autosomes in DGN and for whole tissue, cross-tissue, and tissue-specific expression in the GTEx cohort, we tested  $\alpha=0.05,0.5,1.$ 

370

372

373

374

375

376

379

381

383

388

# Quantifying sparsity with Bayesian Sparse Linear Mixed Models (BSLMM)

We used BSLMM [20] to model the effect of local genetic variation (SNPs within 1 Mb of gene) on the genetic architecture of gene expression. The BSLMM is a linear model with a polygenic component (small effects) and a sparse component (large effects) enforced by sparsity inducing priors on the regression coefficients [20]. We used the software GEMMA [43] to implement BSLMM for each gene with 100K sampling steps per gene. The BSLMM estimates the PVE (the proportion of variance in phenotype explained by the additive genetic model, analogous to the chip heritability in GCTA) and PGE (the proportion of genetic variance explained by the sparse effects terms where 0 means that genetic effect is purely polygenic and 1 means that the effect is purely sparse). From the second half of the sampling iterations for each gene, we report the median and the 95% credible sets of the PVE, PGE, and the  $|\gamma|$  parameter (the number of SNPs with non-zero coefficients).

# Orthogonal Tissue Decomposition

We use a mixed effects model to decompose the expression level of a gene into a subject specific and subject by tissue specific components. The expression of a gene for individual i in tissue t,  $Y_{i,t}$ , is modeled as

$$Y_{i,t} = Y_i^{\text{CT}} + Y_{i,t}^{\text{TS}} + \mathbf{Z}_i \boldsymbol{\beta} + \epsilon_{i,t}$$

where  $Y_i^{\text{CT}}$  is the random subject level intercept,  $Y_{i,t}^{\text{TS}}$  is the random subject by tissue intercept,  $\mathbf{Z}_i$  represents covariates (for overall intercept, tissue intercept, gender, and PEER factors), and  $\epsilon_{i,t}$  is the error term. We assume  $Y_i^{\text{CT}} \sim N(0, \sigma_{\text{CT}}^2)$ ,  $Y_{i,t}^{\text{TS}} \sim N(0, \sigma_{\text{TS}}^2)$ ,  $\epsilon \sim N(0, \sigma_{\epsilon}^2)$ , and all three independent of each other.

For the cross tissue component to be identifiable, multiple replicates of expression is needed for each subject. In the same vein, for the tissue specific component to be identifiable multiple replicates of expression is needed for a given tissue/subject pair.

GTEx [23] data consisted of measurement of expression for multiple tissues for each subject, thus multiple replications per subject. However, there were very few replicated

measurement for a given tissue/subject pair. Thus, we fit the reduced model and use the estimates of the residual as the tissue specific component.

$$Y_{i,t} = Y_i^{\text{CT}} + \mathbf{Z}_i \boldsymbol{\beta} + \epsilon_{i,t}$$

The mixed effects model parameters were estimated using the lme4 package [44] in R [45]. Batch effects and unmeasured confounders were accounted for using 15 PEER factors computed with the PEER [29] package in R. Posterior modes of the subject level random intercepts were used as estimates of the cross tissue components whereas the residuals of the models were used as tissue specific components.

The model included whole tissue gene expression levels in 8555 GTEx tissue samples from 544 unique subjects. A total of 17,647 Protein-coding genes (defined by GENCODE [40] version 18) with a mean gene expression level across tissues greater than 0.1 RPKM (reads per kilobase of transcript per million reads mapped) and RPKM > 0 in at least 3 individuals were included in the model.

# Comparison of OTD trait heritability with multi-tissue eQTL results

To verify that the newly derived cross tissue and tissue specific traits were capturing the expected properties we used the results of the multi-tissue eQTL analysis performed by Flutre et al. [28] on nine tissues from the pilot phase of the GTEx project [23]. In particular, we used the posterior probability of a gene being actively regulated (PPA) in a tissue downloaded from the GTEx portal at

http://www.gtexportal.org/static/datasets/gtex\_analysis\_pilot\_v3/multi\_tissue\_eqtls/Multi\_tissue\_eQTL\_GTEx\_Pilot\_Phase\_datasets.tar.

We reasoned that genes with large cross tissue component (i.e. high cross-tissue  $h^2$ ) would have more uniform PPA across tissues. Thus we defined for each gene a measure of uniformity,  $U_g$ , across tissues based on the nine dimensional vector of PPAs using the entropy formula. More specifically, we divided each vector of PPA by their sum across

421

423

425

426

430

431

432

435

437

tissues and computed the measure of uniformity as follows:

$$U_g = -\sum_t p_{t,g} \log p_{t,g}$$

where  $p_{t,g}$  is the normalized PPA for gene g and tissue t.

# Acknowledgments

We thank Nicholas Knoblauch and Jason Torres for initial pipeline development and planning. We thank Nicholas Miller for assistance building the results database.

Grants

We acknowledge the following US National Institutes of Health grants: R01MH107666 (H.K.I.), K12 CA139160 (H.K.I.), T32 MH020065 (K.P.S.), R01 MH101820 (GTEx), P30 DK20595 and P60 DK20595 (Diabetes Research and Training Center), P50 DA037844 (Rat Genomics), P50 MH094267 (Conte). H.E.W. was supported in part by start-up funds from Loyola University Chicago.

GTEx data. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health (commonfund.nih.gov/GTEx). Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled at Biospecimen Source Sites funded by NCI Leidos Biomedical Research, Inc. subcontracts to the National Disease Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract (HHSN268201000029C) to the The Broad Institute, Inc. Biorepository operations were funded through a Leidos Biomedical Research, Inc. subcontract to Van Andel Research Institute (10ST1035). Additional data repository and project management were provided by Leidos Biomedical Research, Inc.(HHSN261200800001E). The Brain Bank was supported supplements to University of Miami grant DA006227. Statistical Methods development grants were made to the University of Geneva (MH090941 & MH101814), the University of Chicago

451

453

454

456

463

(MH090951,MH090937, MH101825, & MH101820), the University of North Carolina - Chapel Hill (MH090936), North Carolina State University (MH101819),Harvard University (MH090948), Stanford University (MH101782), Washington University (MH101810), and to the University of Pennsylvania (MH101822). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000424.v3.p1.

**DGN data.** NIMH Study 88 – Data was provided by Dr. Douglas F. Levinson. We gratefully acknowledge the resources were supported by National Institutes of Health/National Institute of Mental Health grants 5RC2MH089916 (PI: Douglas F. Levinson, M.D.; Coinvestigators: Myrna M. Weissman, Ph.D., James B. Potash, M.D., MPH, Daphne Koller, Ph.D., and Alexander E. Urban, Ph.D.) and 3R01MH090941 (Co-investigator: Daphne Koller, Ph.D.).

Framingham data. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI.

Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL- 64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University. Funding for Affymetrix genotyping of the FHS Omni cohorts was provided by Intramural NHLBI funds from Andrew D. Johnson and Christopher J. O?Donnell.

Additional funding for SABRe was provided by Division of Intramural Research, NHLBI, and Center for Population Studies, NHLBI.

The following datasets were downloaded from dbGaP: phs000363.v12.p9 and phs000342.v13.p9.

Computing resources.

471

473

475

476

478

481

483

487

490

492

**OSDC** This work made use of the Open Science Data Cloud (OSDC) which is an Open Cloud Consortium (OCC)-sponsored project. This work was supported in part by grants from Gordon and Betty Moore Foundation and the National Science Foundation and major contributions from OCC members like the University of Chicago [46].

Bionimbus This work made use of the Bionimbus Protected Data Cloud (PDC), which is a collaboration between the Open Science Data Cloud (OSDC) and the IGSB (IGSB), the Center for Research Informatics (CRI), the Institute for Translational Medicine (ITM), and the University of Chicago Comprehensive Cancer Center (UCCCC). The Bionimbus PDC is part of the OSDC ecosystem and is funded as a pilot project by the NIH [47]

(https://www.bionimbus-pdc.opensciencedatacloud.org/).

# References

- Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ.
   Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS. PLoS Genetics. 2010;6(4):e1000888. Available from: http://dx.doi.org/10.1371/journal.pgen.1000888.
- Nica AC, Montgomery SB, Dimas AS, Stranger BE, Beazley C, Barroso I, et al. Candidate Causal Regulatory Effects by Integration of Expression QTLs with Complex Trait Genetic Associations. PLoS Genetics. 2010;6(4):e1000895.
   Available from: http://dx.doi.org/10.1371/journal.pgen.1000895.
- Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, et al.
   Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11
   Common Diseases. The American Journal of Human Genetics.
   2014;95(5):535-552. Available from:
   <a href="http://dx.doi.org/10.1016/j.ajhg.2014.10.004">http://dx.doi.org/10.1016/j.ajhg.2014.10.004</a>.
- 4. Torres JM, Gamazon ER, Parra EJ, Below JE, Valladares-Salgado A, Wacher N, et al. Cross-tissue and tissue-specific eQTLs: partitioning the heritability of a complex trait. The American Journal of Human Genetics. 2014;95(5):521–534.

503

505

- Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;.
- Albert FW, Kruglyak L. The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015;16(4):197–212. Available from: http://dx.doi.org/10.1038/nrg3891.
- 7. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of Cis Regulatory Variation in Diverse Human Populations. PLoS Genetics. 2012;8(4):e1002639. Available from: http://dx.doi.org/10.1371/journal.pgen.1002639.
- Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, et al. Population genomics of human gene expression. Nature Genetics. 2007;39(10):1217–1224. Available from: http://dx.doi.org/10.1038/ng2142.
- Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, et al. Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue. PLoS Genetics. 2011;7(5):e1002078. Available from: http://dx.doi.org/10.1371/journal.pgen.1002078.
- 10. Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K, et al. Heritability and genomics of gene expression in peripheral blood. Nature Genetics. 2014 apr;46(5):430-437. Available from: http://dx.doi.org/10.1038/ng.2951.
- Price AL, Helgason A, Thorleifsson G, McCarroll SA, Kong A, Stefansson K. Single-Tissue and Cross-Tissue Heritability of Gene Expression Via Identity-by-Descent in Related or Unrelated Individuals. PLoS Genetics. 2011;7(2):e1001317. Available from: http://dx.doi.org/10.1371/journal.pgen.1001317.
- 12. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; Available from: http://dx.doi.org/10.1038/nature08185.

- Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nature Genetics. 2012;44(5):483-489. Available from: http://dx.doi.org/10.1038/ng.2232.
- 14. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics. 2012;44(9):981–990. Available from: http://dx.doi.org/10.1038/ng.2383.
- 15. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene-based association method for mapping traits using reference transcriptome data. Nature Genetics. 2015;47(9):1091–1098. Available from: http://dx.doi.org/10.1038/ng.3367.
- Tibshirani R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society Series B (Methodological). 2015;58(1):267–288.
   Available from: http://www.jstor.org/stable/2346178.
- 17. Hoerl AE, Kennard RW. Ridge Regression: Applications to Nonorthogonal Problems. Technometrics. 1970;12(1):69–82. Available from: http://dx.doi.org/10.1080/00401706.1970.10488635.
- de los Campos G, Gianola D, Allison DB. Predicting genetic predisposition in humans: the promise of whole-genome markers. Nat Rev Genet.
   2010;11(12):880-886. Available from: http://dx.doi.org/10.1038/nrg2898.
- 19. Wheeler HE, Aquino-Michaels K, Gamazon ER, Trubetskoy VV, Dolan ME, Huang RS, et al. Poly-Omic Prediction of Complex Traits: OmicKriging. Genetic Epidemiology. 2014;38(5):402–415. Available from: http://dx.doi.org/10.1002/gepi.21808.
- 20. Zhou X, Carbonetto P, Stephens M. Polygenic Modeling with Bayesian Sparse Linear Mixed Models. PLoS Genetics. 2013;9(2):e1003264. Available from: http://dx.doi.org/10.1371/journal.pgen.1003264.

- 21. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature. 2005;437(7063):1365–1369. Available from: http://dx.doi.org/10.1038/nature04244.
- 22. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Research. 2013;24(1):14-24. Available from: http://dx.doi.org/10.1101/gr.155192.113.
- 23. Ardlie KG, Deluca DS, Segre AV, Sullivan TJ, Young TR, Gelfand ET, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 2015;348(6235):648–660. Available from: http://dx.doi.org/10.1126/science.1262110.
- 24. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex Trait Analysis. The American Journal of Human Genetics. 2011;88(1):76-82. Available from: http://dx.doi.org/10.1016/j.ajhg.2010.11.011.
- 25. Pierce BL, Tong L, Chen LS, Rahaman R, Argos M, Jasmine F, et al. Mediation Analysis Demonstrates That Trans-eQTLs Are Often Explained by Cis-Mediation: A Genome-Wide Analysis among 1,800 South Asians. PLoS genetics. 2014;10(12):e1004818.
- 26. Zhang X, Joehanes R, Chen BH, Huan T, Ying S, Munson PJ, et al. Identification of common genetic variants controlling transcript isoform variation in human whole blood. Nature Genetics. 2015;47(4):345–352. Available from: http://dx.doi.org/10.1038/ng.3220.
- 27. Zou H, Hastie T. Regularization and variable selection via the elastic net. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2005;67(2):301-320. Available from: http://dx.doi.org/10.1111/j.1467-9868.2005.00503.x.

- Flutre T, Wen X, Pritchard J, Stephens M. A Statistical Framework for Joint eQTL Analysis in Multiple Tissues. PLoS Genetics. 2013;9(5):e1003486.
   Available from: http://dx.doi.org/10.1371/journal.pgen.1003486.
- 29. Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 2012;7(3):500–507. Available from: http://dx.doi.org/10.1038/nprot.2011.457.
- Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3(9):1724–1735.
- 31. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nature Genetics. 2012;44(8):955–959. Available from: http://dx.doi.org/10.1038/ng.2354.
- 32. Fuchsberger C, Abecasis GR, Hinds DA. minimac2: faster genotype imputation. Bioinformatics. 2014;31(5):782-784. Available from: http://dx.doi.org/10.1093/bioinformatics/btu704.
- 33. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic acids research. 2003;31(4):e15-e15.
- 34. MacDonald JW. huex10stprobeset.db: Affymetrix huex10 annotation data (chip huex10stprobeset). R package; version 8.3.1.
- 35. MacDonald JW. huex10sttranscriptcluster.db: Affymetrix huex10 annotation data (chip huex10sttranscriptcluster). R package; version 8.3.1.
- 36. Chang CC, Chow CC, Tellier L, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(7).
- 37. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nature methods. 2012;9(2):179–181.

- 38. McCarthy S, Das S, Kretzschmar W, Durbin R, Abecasis G, Marchini J. A reference panel of 64,976 haplotypes for genotype imputation. bioRxiv. 2015;p. 035170.
- 39. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28(10):1353–1358.
- 40. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Research. 2012;22(9):1760–1774. Available from: http://dx.doi.org/10.1101/gr.135350.111.
- 41. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of Statistical Software. 2010;33(1):1–22. Available from: http://www.jstatsoft.org/v33/i01/.
- 42. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. Journal of Statistical Software. 2011;39(5):1–13. Available from: http://www.jstatsoft.org/v39/i05/.
- 43. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nature Genetics. 2012;44(7):821-824. Available from: http://dx.doi.org/10.1038/ng.2310.
- 44. Bates D, Mächler M, Bolker BM, Walker S. Fitting Linear Mixed-Effects Models using lme4. Journal of Statistical Software. 2015;67(1):1–48. Available from: http://dx.doi.org/10.18637/jss.v067.i01.
- 45. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2015. Available from: http://www.R-project.org/.
- 46. Grossman RL, Greenway M, Heath AP, Powell R, Suarez RD, Wells W, et al. The design of a community science cloud: The open science data cloud perspective. In: High Performance Computing, Networking, Storage and Analysis (SCC), 2012 SC Companion:. IEEE; 2012. p. 1051–1057.


47. Heath AP, Greenway M, Powell R, Spring J, Suarez R, Hanley D, et al.

Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets.

Journal of the American Medical Informatics Association. 2014;21(6):969–975.


# **Supporting Information**

## S1 Fig




GTEx whole tissue distal heritability (h²) estimation. Distal (SNPs that are eQTLs in the Framingham Heart Study on other chromosomes [FDR < 0.05]) gene expression h² estimates from a joint model in the nine GTEx tissues with the largest sample sizes are ordered by increasing h². The 95% confidence interval (CI) of each h² estimate is in gray and significant genes (P < 0.05) are in blue. Less than 1% of genes show significant distal h².

# S2 Fig




GTEx whole tissue cross-validated predictive performance across the elastic net. The difference between the cross validated  $R^2$  of the LASSO model and the elastic net model mixing parameters 0.05 and 0.5 for autosomal protein coding genes per tissue. Elastic net with  $\alpha=0.5$  values hover around zero, meaning that it has similar predictive performance to LASSO. The  $R^2$  difference of the more polygenic model (elastic net with  $\alpha=0.05$ ) is mostly above the 0 line, indicating that this model performs worse than the LASSO model across tissues.

# S3 Fig



Cross-tissue and whole tissue comparison of heritability  $(h^2, A)$  and standard error (SE, B). Cross-tissue local  $h^2$  is estimated using the cross-tissue component (random effects) of the mixed effects model for gene expression and SNPs within 1 Mb of each gene. Whole tissue local  $h^2$  is estimated using the measured gene expression for each respective tissue and SNPs within 1 Mb of each gene. Estimates of  $h^2$  for cross-tissue expression traits are larger and their standard errors are smaller than the corresponding estimates for each whole tissue expression trait.


# S4 Fig



## GTEx whole tissue expression Bayesian Sparse Linear Mixed Model.


Comparison of median PGE (proportion of PVE explained by sparse effects) to median PVE (total proportion of variance explained, the BSLMM equivalent of  $h^2$ ) for expression of each gene. The 95% credible set of each PGE estimate is in gray and genes with a lower credible set (LCS) greater than 0.01 are in blue. For highly heritable genes the sparse component is close to 1, thus for high heritability genes the local architecture is sparse across tissues. For lower heritability genes, there is not enough evidence to determine sparsity or polygenicity.

# S5 Fig




GTEx orthogonal tissue decomposition cross-tissue and tissue-specific expression Bayesian Sparse Linear Mixed Model. Comparison of median PGE (proportion of PVE explained by sparse effects) to median PVE (total proportion of variance explained, the BSLMM equivalent of  $\rm h^2$ ) for expression of each gene. The 95% credible set of each PGE estimate is in gray and genes with a lower credible set (LCS) greater than 0.01 are in blue. For highly heritable genes the sparse component is close to 1, thus for high heritability genes the local architecture is sparse across tissues. About twice as many cross-tissue expression traits have significant PGE (LCS > 0.01) compared to the tissue-specific expression traits.

# S6 Fig



Cross-tissue and tissue-specific comparison of heritability (h<sup>2</sup>, A) and standard error (SE, B) estimation. Cross-tissue local h<sup>2</sup> is estimated using the cross-tissue component (random effects) of the mixed effects model for gene expression and SNPs within 1 Mb of each gene. Tissue-specific local h<sup>2</sup> is estimated using the tissue-specific component (residuals) of the mixed effects model for gene expression for each respective tissue and SNPs within 1 Mb of each gene. Estimates of h<sup>2</sup> for cross-tissue expression traits are larger and their standard errors are smaller than the corresponding estimates for each tissue-specific expression trait.

# S7 Fig



GTEx orthogonal tissue decomposition cross-tissue and tissue-specific expression cross-validated predictive performance across the elastic net. The difference between the cross validated  $R^2$  of the LASSO model and the elastic net model mixing parameters 0.05 and 0.5 for autosomal protein coding genes per cross-tissue and tissue-specific gene expression traits. Elastic net with  $\alpha=0.5$  values hover around zero, meaning that it has similar predictive performance to LASSO. The  $R^2$  difference of the more polygenic model (elastic net with  $\alpha=0.05$ ) is mostly above the 0 line, indicating that this model performs worse than the LASSO model across decomposed tissues.

## S1 Table

S1 Table. Estimates of cross-tissue and tissue-specific local  $h^2$ . Expression levels derived by Orthogonal Tissue Decomposition and  $h^2$  estimated using the --reml-no-constrain method.

tissue         n         mean $h^2$ (SE)         % $P < 0.05$ num $P < 0.05$ num expressed           Cross-tissue         450 $0.062$ ( $0.0008$ )         35.4         6003         16951           Adipose - Subcutaneous         298 $0.017$ ( $0.0004$ )         10.3         1747         16951           Adrenal Gland         126 $0.037$ ( $0.0007$ )         10.2         1731         16951           Artery - Aorta         198 $0.022$ ( $0.0005$ )         10.2         1733         16951           Artery - Coronary         119 $0.048$ ( $0.0008$ )         12.2         2066         16951           Artery - Tibial         285 $0.022$ ( $0.0004$ )         13.3         2262         16951           Brain - Anterior cingulate cortex (BA24)         72 $0.037$ ( $0.0012$ )         8.6         1451         16951           Brain - Caudate (basal ganglia)         100 $0.042$ ( $0.0009$ )         9.8         1659         16951           Brain - Cerebellur Hemisphere         89 $0.046$ ( $0.0011$ )         10.2         1730         16951           Brain - Cerebellum         103 $0.041$ ( $0.0009$ )         10.8         1825         16951           Brain - Frontal C
Adipose - Subcutaneous       298       0.017 (0.0004)       10.3       1747       16951         Adrenal Gland       126       0.037 (0.0007)       10.2       1731       16951         Artery - Aorta       198       0.022 (0.0005)       10.2       1733       16951         Artery - Coronary       119       0.048 (0.0008)       12.2       2066       16951         Artery - Tibial       285       0.022 (0.0004)       13.3       2262       16951         Brain - Anterior cingulate cortex (BA24)       72       0.037 (0.0012)       8.6       1451       16951         Brain - Caudate (basal ganglia)       100       0.042 (0.0009)       9.8       1659       16951         Brain - Cerebellar Hemisphere       89       0.046 (0.0011)       10.2       1730       16951         Brain - Cerebellum       103       0.041 (0.0009)       10.8       1825       16951         Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hypothalamus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Nucleus accumbe
Artery - Aorta       198       0.022 (0.0005)       10.2       1733       16951         Artery - Coronary       119       0.048 (0.0008)       12.2       2066       16951         Artery - Tibial       285       0.022 (0.0004)       13.3       2262       16951         Brain - Anterior cingulate cortex (BA24)       72       0.037 (0.0012)       8.6       1451       16951         Brain - Caudate (basal ganglia)       100       0.042 (0.0009)       9.8       1659       16951         Brain - Cerebellar Hemisphere       89       0.046 (0.0011)       10.2       1730       16951         Brain - Cerebellum       103       0.041 (0.0009)       10.8       1825       16951         Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mam
Artery - Coronary       119       0.048 (0.0008)       12.2       2066       16951         Artery - Tibial       285       0.022 (0.0004)       13.3       2262       16951         Brain - Anterior cingulate cortex (BA24)       72       0.037 (0.0012)       8.6       1451       16951         Brain - Caudate (basal ganglia)       100       0.042 (0.0009)       9.8       1659       16951         Brain - Cerebellar Hemisphere       89       0.046 (0.0011)       10.2       1730       16951         Brain - Cerebellum       103       0.041 (0.0009)       10.8       1825       16951         Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cell
Artery - Tibial       285       0.022 (0.0004)       13.3       2262       16951         Brain - Anterior cingulate cortex (BA24)       72       0.037 (0.0012)       8.6       1451       16951         Brain - Caudate (basal ganglia)       100       0.042 (0.0009)       9.8       1659       16951         Brain - Cerebellur Hemisphere       89       0.046 (0.0011)       10.2       1730       16951         Brain - Cerebellum       103       0.041 (0.0009)       10.8       1825       16951         Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       82       0.033 (0.0010)       7.8       1321       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951
Brain - Anterior cingulate cortex (BA24)         72         0.037 (0.0012)         8.6         1451         16951           Brain - Caudate (basal ganglia)         100         0.042 (0.0009)         9.8         1659         16951           Brain - Cerebellar Hemisphere         89         0.046 (0.0011)         10.2         1730         16951           Brain - Cerebellum         103         0.041 (0.0009)         10.8         1825         16951           Brain - Cortex         96         0.053 (0.0010)         10.6         1803         16951           Brain - Frontal Cortex (BA9)         92         0.037 (0.0009)         8.4         1418         16951           Brain - Hippocampus         81         0.033 (0.0010)         7.6         1292         16951           Brain - Hypothalamus         81         0.020 (0.0011)         7.8         1321         16951           Brain - Nucleus accumbens (basal ganglia)         93         0.040 (0.0010)         8.9         1511         16951           Brain - Putamen (basal ganglia)         82         0.033 (0.0010)         7.8         1323         16951           Breast - Mammary Tissue         183         0.020 (0.0005)         7.7         1307         16951           Cells - EBV-transf
Brain - Caudate (basal ganglia)         100         0.042 (0.0009)         9.8         1659         16951           Brain - Cerebellar Hemisphere         89         0.046 (0.0011)         10.2         1730         16951           Brain - Cerebellum         103         0.041 (0.0009)         10.8         1825         16951           Brain - Cortex         96         0.053 (0.0010)         10.6         1803         16951           Brain - Frontal Cortex (BA9)         92         0.037 (0.0009)         8.4         1418         16951           Brain - Hippocampus         81         0.033 (0.0010)         7.6         1292         16951           Brain - Hypothalamus         81         0.020 (0.0011)         7.8         1321         16951           Brain - Nucleus accumbens (basal ganglia)         93         0.040 (0.0010)         8.9         1511         16951           Brain - Putamen (basal ganglia)         82         0.033 (0.0010)         7.8         1323         16951           Breast - Mammary Tissue         183         0.020 (0.0005)         7.7         1307         16951           Cells - EBV-transformed lymphocytes         115         0.045 (0.0008)         10.8         1833         16951           Cells - Transformed f
Brain - Caudate (basal ganglia)         100         0.042 (0.0009)         9.8         1659         16951           Brain - Cerebellar Hemisphere         89         0.046 (0.0011)         10.2         1730         16951           Brain - Cerebellum         103         0.041 (0.0009)         10.8         1825         16951           Brain - Cortex         96         0.053 (0.0010)         10.6         1803         16951           Brain - Frontal Cortex (BA9)         92         0.037 (0.0009)         8.4         1418         16951           Brain - Hippocampus         81         0.033 (0.0010)         7.6         1292         16951           Brain - Hypothalamus         81         0.020 (0.0011)         7.8         1321         16951           Brain - Nucleus accumbens (basal ganglia)         93         0.040 (0.0010)         8.9         1511         16951           Brain - Putamen (basal ganglia)         82         0.033 (0.0010)         7.8         1323         16951           Breast - Mammary Tissue         183         0.020 (0.0005)         7.7         1307         16951           Cells - EBV-transformed lymphocytes         115         0.045 (0.0008)         10.8         1833         16951           Cells - Transformed f
Brain - Cerebellum       103       0.041 (0.0009)       10.8       1825       16951         Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Cortex       96       0.053 (0.0010)       10.6       1803       16951         Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Frontal Cortex (BA9)       92       0.037 (0.0009)       8.4       1418       16951         Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Hippocampus       81       0.033 (0.0010)       7.6       1292       16951         Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Hypothalamus       81       0.020 (0.0011)       7.8       1321       16951         Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Nucleus accumbens (basal ganglia)       93       0.040 (0.0010)       8.9       1511       16951         Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Brain - Putamen (basal ganglia)       82       0.033 (0.0010)       7.8       1323       16951         Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Breast - Mammary Tissue       183       0.020 (0.0005)       7.7       1307       16951         Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Cells - EBV-transformed lymphocytes       115       0.045 (0.0008)       10.8       1833       16951         Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Cells - Transformed fibroblasts       272       0.019 (0.0004)       10.6       1805       16951         Colon - Sigmoid       124       0.024 (0.0007)       9.0       1530       16951
Colon - Sigmoid 124 0.024 (0.0007) 9.0 1530 16951
Colon Transports 170 0.099 (0.0005) 8.6 1469 16051
Colon - Transverse $170 - 0.022 (0.0003) = 0.0 = 1402 = 10991$
Esophagus - Gastroesophageal Junction 127 0.029 (0.0007) 8.9 1512 16951
Esophagus - Mucosa 242 0.026 (0.0005) 13.7 2319 16951
Esophagus - Muscularis 219 0.024 (0.0005) 11.0 1871 16951
Heart - Atrial Appendage 159 0.031 (0.0006) 9.4 1601 16951
Heart - Left Ventricle $190  0.025  (0.0005)$ $11.2  1894  16951$
Liver 98 0.036 (0.0009) 8.9 1506 16951
Lung 279 0.018 (0.0004) 10.7 1819 16951
Muscle - Skeletal 361 0.020 (0.0003) 13.1 2223 16951
Nerve - Tibial 256 0.026 (0.0004) 13.3 2250 16951
Ovary $85  0.043 \ (0.0009)$ $7.8  1323  16951$
Pancreas $150 \ 0.036 \ (0.0007)$ $11.6$ $1969$ $16951$
Pituitary 87 0.044 (0.0010) 9.4 1590 16951
Skin - Not Sun Exposed (Suprapubic) 196 0.041 (0.0005) 19.2 3249 16951
Skin - Sun Exposed (Lower leg) 303 0.027 (0.0004) 17.3 2939 16951
Small Intestine - Terminal Ileum 77 0.046 (0.0011) 7.9 1340 16951
Spleen 89 0.062 (0.0010) 10.7 1820 16951
Stomach 171 0.020 (0.0005) 8.3 1406 16951
Testis $157  0.042 \ (0.0007) \qquad 14.0 \qquad 2378 \qquad 16951$
Thyroid 279 0.024 (0.0004) 13.3 2250 16951
Whole Blood 339 0.025 (0.0004) 17.7 3004 16951

All tissues are from the GTEx Project. Mean heritability ( $h^2$ ) and the standard error of the mean (SE) are calculated across genes for each tissue. The percentage (%) and number (num) of genes with significant  $h^2$  estimates (P < 0.05) and the number of genes expressed in each tissue are also reported.